Your current location:

Home > R&D Platform > Viral Vector Platform

Purchase

Top

Binhui's Viral Vector Platform

The highly scalable oHSV2-based platform
Core Product: BS001 (OH2 injection)

1)Deletion of neurotoxic factor ICP34.5, promote selective viral replication in tumor cells, enhance safety.

2)Deletion of immune suppressive gene ICP47, promote antigen presentation and viral replication, enhance anti-tumor efficacy.

3)Insert GM-CSF, to induce stronger, durable and specific anti-tumor immune responses.

Viral Vector Platform Progress

Candidates

Indication

Pre-clinical

IND

Dose Escalation (Phase I)

Dose Extension (Phase II)

Pivotal Study (Phase III)

Oncolytic virus
BS001(CN)

Melanoma

GBM

mCRC

Others

BS001(US)

Melanoma with αPD-1 failure

BS001 combo with αPD-1 (CN)

mCRC

Sarcoma

BS006(CN)

Solid tumors(IIT)

BS006(US)

Solid tumors

BS008(US)

Solid tumors

Binhui's Nucleic acid drug platform

BH-RACE platform of nucleic acid drug

Product process

Binhui's robust pilot production process with own patents
mRNA vaccine for infectious diseases

S-protein trimer mRNA vaccine

Monkeypox vaccine

Rabies vaccine

Tumor vaccine

Neo-antigen tumor vaccines

Heterologous tumor mRNA vaccines

Gene therapy delivery vector

In vivo CAR-T

In vivo CAR-NK

Nucleic Acid Platform Progress

Candidates

Indication

Pre-clinical

IND

Dose Escalation (Phase I)

Dose Extension (Phase II)

Pivotal Study (Phase III)

Nucleic acid drug

Oncolytic LNP

Solid tumors

Protein replacement drugs

Vaccine/Anti-muscle spasm/Anti-wrinkle

Binhui's Protein Platform

Unique protein purification process

Protein Platform Progress

Candidates

Indication

Pre-clinical

IND

Dose Escalation (Phase I)

Dose Extension (Phase II)

Pivotal Study (Phase III)

Protein

Universal
affinity
chromatography products

/

Vaccine

Human and pets

Binhui's Cell Therapy Platform

Cell Therapy Platform Progress

Candidates

Indication

Pre-clinical

IND

Dose Escalation (Phase I)

Dose Extension (Phase II)

Pivotal Study (Phase III)

Cell Therapy

VAK(CN)

Malignant pleural and abdominal effusions(IIT)

VAK(US)

Malignant pleural and abdominal effusions